HIF prolyl-hydroxylase inhibitor

From Wikipedia, the free encyclopedia
Jump to: navigation, search

HIF prolyl-hydroxylase inhibitors are members of a class of new drugs that act on the hypoxia-inducible factor (HIF) pathway. They are being investigated for treatment of anemia, chronic kidney disease,[1] cancer,[2] and for their effects on heart tissue[3] and others.[4] Research conducted in mice suggests that they may increase hippocampal memory by increasing erythropoietin expression.[5]

References[edit]

  1. ^ Warnecke, C.; Griethe, W.; Weidemann, A.; Jurgensen, J. S.; Willam, C.; Bachmann, S.; Ivashchenko, Y.; Wagner, I.; Frei, U.; Wiesener, M.; Eckardt, K.-U. (2003). "Activation of the hypoxia-inducible factor pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors". The FASEB Journal. doi:10.1096/fj.02-1062fje. 
  2. ^ Ivan, Mircea (2006). "HIF-PROLYL hydroxylase inhibitors: From basic science to clinical trials". MÆDICA - a Journal of Clinical Medicine 1 (2): 67–69. ISSN 1841-9038. 
  3. ^ Nangaku, M.; Izuhara, Y.; Takizawa, S.; Yamashita, T.; Fujii-Kuriyama, Y.; Ohneda, O.; Yamamoto, M.; Van Ypersele De Strihou, C. et al. (2007). "A Novel Class of Prolyl Hydroxylase Inhibitors Induces Angiogenesis and Exerts Organ Protection Against Ischemia". Arteriosclerosis, Thrombosis, and Vascular Biology 27 (12): 2548. doi:10.1161/ATVBAHA.107.148551. 
  4. ^ "FibroGen Reports New Research on Development of HIF Prolyl Hydroxylase Inhibitors Related to Endothelial Progenitor Cells, Anti-Inflammation, Cytoprotection and Erythropoiesis". drugs.com. 2008. 
  5. ^ Adamcio, B; Sperling, S; Hagemeyer, N; Walkinshaw, G; Ehrenreich, H (2010). "Hypoxia inducible factor stabilization leads to lasting improvement of hippocampal memory in healthy mice". Behavioural brain research 208 (1): 80–4. doi:10.1016/j.bbr.2009.11.010. PMID 19900484. 

See also[edit]